Home·Explore by biomarker·IDH2

IDH2

Biomarker

IDH2 mutations are implicated in metabolic dysregulation in cancer. They serve as therapeutic targets in acute myeloid leukemia and related disorders.

Approvals
2
Indications
2
Therapies
2
Mapped tests
2

Where this biomarker is used

Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.

Indication-specific approvals

Approvals where IDH2 is defined directly in the indication labeling.

IndicationBiomarker criteriaTherapies
Acute Myeloid Leukemia (AML)
Heme · Leukemia
  • R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W
IDHIFA
Astrocytoma and Oligodendroglioma
Solid Tumor · Brain
  • IDH1 R132C, IDH1 R132G, IDH1 R132H, IDH1 R132L, IDH1 R132S, IDH2 R172M, IDH2 R172K, IDH2 R172W, IDH2 R172S, and IDH2 R172G mutations
VORANIGO
Tumor-agnostic approvals

Approvals defined at the solid tumor level where IDH2 is part of the eligibility criteria.

No tumor-agnostic approvals are currently mapped for this biomarker.

Tests that measure this biomarker

These assays report IDH2 as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.

Test
Abbott RealTime IDH2
Abbott Molecular, Inc.
Method
PCR
Specimen
Whole blood

Reports IDH2 as part of its biomarker panel.

1 approvalView test profile →
Test
Oncomine Dx Target Test
Life Technologies Corporation
Method
NGS
Specimen
Tissue (FFPE)

Reports IDH2 as part of its biomarker panel.

1 approvalView test profile →
This view is scoped to IDH2. You can also see how it compares with other biomarkers and indications on the Know Your Companions™ map.